Japan-based Takeda Pharmaceuticals is hoping to raise more than $542 million by selling its headquarters and surrounding buildings in Osaka.
The announcement of the sale comes as the company prepares to buy specialty biopharmaceutical company Shire Plc, which is based in the U.S. and Ireland. The $62-billion deal is expected to put debt pressure on Takeda.
Just days ago, Takeda opened its new global headquarters in Tokyo. The company had been based in Osaka since 1781.
Read the full Reuters report.